Intelligent biopharma - Forging the links across the value chain

The biopharmaceutical sector is facing digital disruption from multiple sources, the chief among them being artificial intelligence (AI) and cloud. Deloitte predicts that in 2019/2020, all industries will accelerate their use of cloud-based AI software and services, including biopharma companies. Among companies that adopt AI technology, 70 percent will obtain AI capabilities through cloud-based enterprise software, and 65 percent will create AI applications using cloud-based development services. In order to keep up with the changing competitive landscape and customer expectations, biopharma companies will need to accelerate their use of AI-enabled services. Biopharma organizations have started using scaled versions of AI over the last 1-2 years in some areas.